Inactive Instrument

Turmeric Acquisition Corp. Stock

Equities

TMPM

KYG9127T1085

Investment Holding Companies

Dynamic Chart
Turmeric Acquisition Corp.(NasdaqCM:TMPM) dropped from NASDAQ Composite Index CI
Turmeric Acquisition to Redeem Shares After Not Consummating Merger MT
Turmeric Acquisition Corp. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022 CI
Turmeric Acquisition Corp. Reports Earnings Results for the First Quarter Ended March 31, 2022 CI
Turmeric Acquisition Corp. Reports Earnings Results for the Full Year Ended December 31, 2021 CI
Turmeric Acquisition Corp. Auditor Raises 'Going Concern' Doubt CI
Turmeric Acquisition Corp. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2021 CI
Turmeric Acquisition Corp. Reports Earnings Results for the Second Quarter Ended June 30, 2021 CI
Turmeric Acquisition Corp. Announces Departure of Vinay Bhaskar, Chief Operating Officer CI
Certain Class B Ordinary Shares of Turmeric Acquisition Corp. are subject to a Lock-Up Agreement Ending on 14-APR-2021. CI
Turmeric Acquisition Corp. Announces Earnings Results for the Period from August 28, 2020 to December 31, 2020 CI
Turmeric Acquisition Corp.(NasdaqCM:TMPM) added to NASDAQ Composite Index CI
Turmeric Acquisition Corp. has completed an IPO in the amount of $85 million. CI
Turmeric Acquisition Corp. has filed an IPO in the amount of $100 million. CI
Turmeric Acquisition Corp. announced that it expects to receive $3.9 million in funding from Turmeric Management, LLC, and other investors CI
More news
Managers TitleAgeSince
Chief Executive Officer 60 -
President 52 -
Director of Finance/CFO 60 -
Members of the board TitleAgeSince
Director/Board Member 60 -
Director/Board Member 65 -
Chairman 53 -
More insiders
Turmeric Acquisition Corp. is a blank check company. The Company is formed for the purpose of effecting a merger, share exchange, asset acquisition, share purchase, reorganization or similar business combination with one or more businesses or entities. The Company intends to identify opportunities in the biotechnology sector, with an emphasis on oncology and rare disease therapeutics. The Company has not conducted any operations and has not generated any revenues.
More about the company